Crinetics Pharmaceuticals CRNX Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$127.85M-32.1% | -$122.82M-52.4% | -$130.09M-69.3% | -$115.64M-56.2% | -$96.77M-44.6% | ||
| $1.16M+25.4% | $994K+26.1% | $1.01M+31.4% | $959K+27.4% | $925K+95.1% | ||
| $29.68M+44.9% | $21.72M+15.3% | $22.7M+25.1% | $26.12M+37.9% | $20.48M+52.2% | ||
| -$20K-5.3% | -$8K— | $0+100% | -$23K— | -$19K+54.8% | ||
| $5.09M— | —— | —— | —— | $0— | ||
| $909K— | —— | —— | —— | $0— | ||
| -$12.06M-790% | —— | —— | $12.52M+140% | -$1.36M-204% | ||
| $7.02M+1.5% | —— | $7.21M+250% | $4.41M+220% | $6.92M+3,363% | ||
| -$428K-18.6% | -$707K-3,922% | —— | —— | -$361K-2,051% | ||
| $703K-13.5% | $654K-13.8% | —— | —— | $813K— | ||
| -$685K+24.1% | -$603K+26.2% | —— | —— | -$903K— | ||
| -$124.7M-41.0% | -$92.9M-38.9% | -$110.72M-76.2% | -$85.85M-80.2% | -$88.45M-67.3% | ||
| $820K-33.8% | $458K-55.5% | $863K+63.4% | $3.2M+235% | $1.24M-7.0% | ||
| $554.43M+41.7% | $213.65M-70.5% | $216.7M+66.7% | $182.88M-4.7% | $391.2M+292% | ||
| $302.89M-1.2% | $271.21M+47.4% | $382.37M+153% | $224.03M+60.8% | $306.48M+202% | ||
| -$252.36M-194% | $57.11M+111% | $164.81M— | $37.95M+171% | -$85.96M-27,919% | ||
| $380.51M— | $0-100% | $0-100% | $0-100% | $0-100% | ||
| $389.88M+8,687% | $26.04M-95.3% | $3.08M-94.6% | $7.06M-6.2% | $4.44M-98.9% | ||
| -$8K— | —— | —— | —— | $0— | ||
| $12.81M+108% | -$9.76M— | —— | -$40.84M— | -$169.98M-150% | ||
| $2.22M-49.3% | $2.73M-34.3% | $3.6M+2.5% | $4.71M+38.3% | $4.38M+13.8% | ||
| -$685K+24.1% | -$603K+26.2% | —— | —— | -$903K— | ||
| $7.02M+1.5% | —— | $7.21M+250% | $4.41M+220% | $6.92M+3,363% | ||
| $703K-13.5% | $654K-13.8% | —— | —— | $813K— | ||
| $302.89M-1.2% | $271.21M+47.4% | $382.37M+153% | $224.03M+60.8% | $306.48M+202% | ||
| $578K— | $0-100% | —— | —— | $0-100% | ||
| —— | $10.15M-9.0% | $10.15M-9.0% | $10.15M-9.0% | $10.15M-9.0% | ||
| $165K— | —— | —— | —— | $0— | ||
| $464K+75.8% | $332K+181% | —— | —— | $264K+57.1% | ||
| -$8K— | —— | —— | —— | $0— | ||
| -$685K+24.1% | -$603K+26.2% | —— | —— | -$903K— | ||
| $3K-80.0% | —— | $4.37M— | $354K— | $15K-98.3% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $920K— | —— | —— | $112K— | $0— | ||
| -$125.52M-40.0% | -$93.36M-37.5% | -$111.58M-76.1% | -$89.05M-83.2% | -$89.69M-65.5% | ||
| -$125.52M-40.0% | -$93.36M-37.5% | -$111.58M-76.1% | -$89.05M-83.2% | -$89.69M-65.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Crinetics Pharmaceuticals's cash flow data come from?
- Every line is extracted from Crinetics Pharmaceuticals's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.